biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 21, 2015) - biOasis (OTCQX:BIOAF)(TSX VENTURE:BTI) and Brigham and Women's Hospital Inc. ("BWH"), Harvard Medical School's distinguished teaching hospital, have entered into a collaboration to pursue work in the area of neuro-oncology.

Dr. Sean Lawler, researcher in the Department of Neurosurgery, Harvard Medical School, will lead the BWH team.

The collaboration intends to initially focus on the advancement to clinic of the Transcend peptide carrier, MTfp, including MTfp-TZM, MTfp-siRNA and MTfp-miRNA within GBM (glioblastoma) models.

BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF)(TSX VENTURE:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it is entered into a Research Collaboration Agreement with Brigham and Women's Hospital Inc.

Using biOasis's Transcend Platform peptide carrier, MTfp, biOasis and researchers lead by Dr. Sean Lawler from the Department of Neurosurgery, Harvard Medical School, will work to deliver a number of compounds targeting glioblastoma tumors within the brain. The initial focus of the collaboration will be on the compounds, MTfp-TZM, MTfp-siRNA and MTfp-miRNA. The work will include moving the trastuzumab program forward towards human clinical trials.

A major teaching hospital of Harvard Medical School, Brigham and Women's Hospital was formed in 1980 with the merger of the Peter Bent Brigham Hospital, the Robert Breck Brigham Hospital, and the Boston Hospital for Women, three of Boston's oldest and most prestigious Harvard Medical School teaching hospitals. The BWH website states that, "The BWH Research Institute (BRI) is one of the most powerful biomedical research institutes in the world and the second largest recipient of National Institutes of Health (NIH) funding among independent hospitals in the United States."

Rob Hutchison, biOasis CEO, stated, "biOasis's Transcend Platform and our peptide carrier, MTfp, have shown exceptional promise in the area of neuro-oncology. As we work towards clinical work in humans, establishing relationships like this with world leaders in the field will be critical. BWH represents the ideal partner for biOasis for this collaboration and over the coming months, we will working closely with Sean and his team and lay out the program pathways. This work shall expand our neuro-oncology program that has so far provided us with such confidence in the Transcend platform and our peptide carrier, MTfp."

About BWH: http://brighamandwomens.org/about_bwh/about_us.aspx

About Transcend

Transcend is biOasis' proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.